

Lateca Med Limited

ABRIDGED UNAUDITED FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED

31 AUGUST 2025

REGISTRATION NUMBER: 676296

Lateca Med Limited

ABRIDGED FINANCIAL STATEMENTS

<i>CONTENTS</i>	<i>PAGE</i>
Directors and other information	1
Balance sheet	3 - 4
Notes to the abridged financial statements	5 - 12

Lateca Med Limited

DIRECTORS AND OTHER INFORMATION

Directors	Angela Leah
Secretary	Leahu Eugeniu
Company Registered Number	676296
Registered office	Lateca Med Limited 6 Cruise Park Walk Tyrrellstown Dublin 15
Business address	6 Cruise Park Walk Tyrrellstown Dublin 15
Accountants	Brophy & Co. Chartered Accountants Unit 7B Supple House Main Street Dunshaughlin Co. Meath
Bankers	Bank Of Ireland Blanchardstown Dublin 15

Lateca Med Limited

For the Year Ended 31 August 2025

Directors' Declaration on Unaudited Financial Statements

In relation to the financial statements as set out on pages 3-12.

- The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.

- The directors confirm that they have made available to Brophy & Co., the company's accounting records and provided all the information necessary for the compilation of the financial statements.

- The directors confirm that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the year ended 31 August 2025.

On behalf of the board



Angela Leah
Director

Lateca Med Limited

BALANCE SHEET AS AT 31 AUGUST 2025

		2025		2024	
Notes	€	€	€	€	€
Fixed assets					
Tangible assets	3		677,051		348,279
Current assets					
Debtors	4	43,855		-	
Cash at bank and in hand		37,577		7,878	
		81,432		7,878	
Creditors:					
Amounts falling due within one year	5	(156,209)		(81,901)	
Net current liabilities			(74,777)		(74,023)
Total assets less current liabilities			602,274		274,256
Creditors: amounts falling due after more than one year	6		(189,525)		-
Provisions for liabilities			-		-
Net assets			412,749		274,256
Capital and reserves					
Called up share capital presented as equity	9		100		100
Profit and loss account	10		412,649		274,156
Shareholders' Funds	11		412,749		274,256

We, as Directors of Lateca Med Limited, state that:

- (a) the company is availing itself of the audit exemption - the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014;
- (b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 is complied with;
- (c) no notice under subsection (1) of section 334 has, in accordance with subsection (2) of that section, been served on the company; and
- (d) the directors acknowledge the obligations of the company, under the Companies Act 2014 to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for that financial year, and otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company.

Lateca Med Limited

We, as directors of Lateca Med Limited, state that - The company has relied on the specified exemption contained in section 352 Companies Act 2014; the company has done so on the grounds that it is entitled to the benefit of that exemption as a company that qualifies for the micro companies regime and confirm that the abridged Financial Statements have been properly prepared in accordance with section 353 Companies Act 2014.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the micro entities regime and in accordance with Financial Reporting Standard 105 'The Financial Reporting Standard applicable to the Micro Entities Regime'. The financial statements were approved by the Board of Directors on and authorised for issue on . They were signed on its behalf by

**Angela Leah
Director**



5th February 2026.

Lateca Med Limited

Notes to the abridged financial statements

Notes to the abridged financial statements

..... continued

1. Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 (the Act) and FRS 105 The Financial Reporting Standard applicable to the Microentities Regime issued by the Financial Reporting Council. The company qualifies as a micro company for the period, as defined by section 280D of the Act, in respect of the financial year and has applied the rules of the 'Micro Companies Regime' in accordance with section 280E of the Act and FRS 105.

Turnover

Turnover is stated net of trade discounts, volume rebates, VAT and similar taxes and derives from the provision of goods and services falling within the company's ordinary activities. Turnover on sale of goods is recognised when the company has transferred the significant risks and rewards of ownership in the goods, which usually takes place when the goods are physically delivered to the buyer. Turnover on supply of services is recognised by reference to the stage of completion of the service at the end of the financial year. The stage of completion is determined primarily on the basis of time costs applied to individual service assignments. Deposits received from customers in advance of completion of sales of goods or in advance of the stage of completion of services at the end of the financial year are not recognised as income and are included in creditors.

Government grants

Grants are recognised at fair value of the asset receivable using the accruals model when there is reasonable assurance that the grant will be received, and all attaching conditions will be complied with. Grants towards capital expenditure are credited to deferred income and are released to the profit and loss account over the expected useful life of the related assets, by equal annual instalments. Grants towards revenue expenditure are released to the profit and loss account as the related expenditure is incurred.

Tangible fixed assets

All tangible fixed assets are initially recorded at historic cost. This includes legal fees, stamp duty and other non-refundable purchase taxes, and also any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in a manner intended by management, which can include the costs of site preparation, initial delivery and handling, installation and assembly, and testing of functionality.

Lateca Med Limited

Notes to the abridged financial statements

..... continued

Depreciation

Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset systematically over its expected useful life, on a straight line basis, as follows:

Freehold buildings	- 4% Straight Line
Fixtures fittings and equipment	- 12.5% Straight Line

Stocks and work in progress

Stocks are stated at the lower of cost and net realisable value using the first in first out method. In the case of finished goods and work in progress, cost is defined as the aggregate cost of raw material, direct labour and the attributable proportion of direct production overheads based on a normal level of capacity. Net realisable value is based on normal selling price, less further costs expected to be incurred to completion and disposal.

At the end of each reporting period, stocks and work in progress are assessed for impairment. If an item (or group of items) is impaired, an impairment loss is recognised.

Retirement Benefits

Retirement benefits for directors are met by payments to a defined contribution pension scheme, which is administered by independent trustees and is financially separate from the company. Contributions are charged to the profit account in the financial year in which they fall due.

Taxation and deferred taxation

The yearly charge for taxation is based on the tax adjusted profit for the financial year and is calculated with reference to the tax rates enacted or substantially enacted at the financial year end date.

Deferred taxation is recognised on the timing differences that have originated but not reversed at the financial year end date where transactions or events that result in an obligation to pay more tax in the future or a right to pay less tax in the future have occurred at the financial year end date. Provision is made at the rates expected to apply when the timing differences reverse. Timing differences are differences between taxable profits and the results as stated in the financial statements that arise from the inclusion of gains and losses in tax assessments in periods different from those in which they are recognised in the financial statements.

A net deferred tax asset is regarded as recoverable and therefore recognised only when, on the basis of all available evidence, it can be regarded as more likely than not that there will be suitable taxable profits from which the future reversal of the underlying timing differences can be deducted.

Lateca Med Limited

Notes to the abridged financial statements

..... continued

Judgments and key sources of estimation uncertainty

The directors consider the accounting estimates and assumptions below to be its critical accounting estimates and judgements:

2. Directors' remuneration and transactions

2 a) Directors' remuneration

Included within staff costs are the following amounts in respect of the directors of the company.

	2025	2024
	€	€
Fees	14,801	-
Directors remuneration	42,030	-
	56,831	-
	56,831	-

The number of directors to whom retirement benefits are accruing under the Pension Scheme Fund is 0 (2024: 0).

Other than as shown above, any further required disclosures in sections 305 and 306 of the Companies Act 2014 are nil for both financial years.

2 b) Transactions with directors and related party transactions

Loan by Director

Angela Leah director and shareholder, advanced monies to the company. The loan is interest free and is repayable on demand, cashflow permitting. The loan is included in Creditors falling due within one year.

	2025	2024
	€	€
At 1 January	-	-
Advances	(25,074)	-
Repayments	42,152	-
At 31 December	17,078	-
	17,078	-

The maximum balance outstanding is €17,078(31 August 2024: €-).

Lateca Med Limited

Notes to the abridged financial statements

..... continued

3. Tangible fixed assets	Land and buildings freehold	Fixtures, fittings and equipment	Total
	€	€	€
<i>Current Financial Year</i>			
<i>Cost</i>			
At 1 September 2024	275,000	73,279	348,279
Additions	20,763	352,719	373,482
At 31 August 2025	<u>295,763</u>	<u>425,998</u>	<u>721,761</u>
<i>Depreciation:</i>			
At 1 September 2024	-	-	-
Charge for the year	-	44,710	44,710
At 31 August 2025	<u>-</u>	<u>44,710</u>	<u>44,710</u>
<i>Net book values:</i>			
At 31 August 2025	<u>295,763</u>	<u>381,288</u>	<u>677,051</u>
At 1 September 2024	<u>275,000</u>	<u>73,279</u>	<u>348,279</u>

4. Debtors	2025	2024
	€	€
Trade debtors (net of provision)	-	-
Other debtors (VAT repayable)	43,855	-
	<u>43,855</u>	<u>-</u>

All debtors fall due within one year.

5. Creditors:	2025	2024
	€	€
Amounts falling due within one year		
Trade creditors	57,409	-
Directors Loan (Note 2)	17,078	-
Amounts owed to credit institutions	28,380	-
Accruals	11,770	-
Other Creditors	41,572	81,901
	<u>156,209</u>	<u>81,901</u>

Lateca Med Limited

Notes to the abridged financial statements

..... continued

	2025	2024
	€	€
6. Creditors: amounts falling due after more than one year		
Amount owed to Credit Institution	189,525	-

7. Details of creditors

Creditors relating to more than one balance sheet item

	2025	2024
	€	€
Amounts due to credit institutions		
Creditors: amounts falling due within one year	28,380	-
Creditors: amounts falling due after more than one year	189,525	-
	217,905	-

	2025	2024
	€	€
Obligations under finance leases and hire purchase contracts		
Creditors: amounts falling due within one year	-	-
Creditors: amounts falling due after more than one year	-	-
	-	-

Debts falling due for repayment after the end of five years

	2025	2024
	€	€
Repayable by installments:		
Bank loans	-	-
Finance leases	-	-
	-	-

Lateca Med Limited

Notes to the abridged financial statements

..... continued

8. Guarantees and other financial commitments

Capital commitments

At the financial year end date the company had the following financial commitments:

	2025	2024
	€	€
Property, plant and equipment	-	-
	<u> </u>	<u> </u>

Finance leases and hire purchase contracts

In addition to the capital commitments set out above, the company has entered into contracts whose inception occurs after the financial year end date amounting to:

	2025	2024
	€	€
Finance leases and hire purchase contracts	-	-
	<u> </u>	<u> </u>

Operating lease commitments

Total future minimum lease payments under non-cancellable operating leases are as follows:

	2025	2024
	€	€
Rental Property	-	-
	<u> </u>	<u> </u>

Retirement benefit commitments

Creditors do not include any amount outstanding in respect of pension contributions to the defined contribution pension scheme. The company has no further commitments in respect of pension commitments at the end of the year (or the previous year) other than those included in the balance sheet.

9. Called up share capital presented as equity

	2025	2024
	€	€
<i>Authorised:</i>		
100,000 Ordinary shares of €1.00 each	100,000	100,000
	<u> </u>	<u> </u>
<i>Allotted, called up and fully paid</i>		
100 Ordinary shares of €1.00 each	100	100
	<u> </u>	<u> </u>

Lateca Med Limited

Notes to the abridged financial statements

..... continued

10. Profit and loss account	Profit and loss account	Total
	€	€
<i>Current Financial Year</i>		
At 1 September 2024	274,256	274,256
Retained profit for the year attributable to equity shareholders	138,393	138,393
At 31 August 2025	<u>412,649</u>	<u>412,649</u>
<i>Prior Financial Year</i>		
At 1 September 2023	219,572	219,572
Retained profit for the year attributable to equity shareholders	54,584	54,584
At 31 August 2024	<u>274,156</u>	<u>274,156</u>
11. Reconciliation of movements in shareholders' funds	2025	2024
	€	€
Total recognised profit for the year	138,393	54,584
<i>Transactions with shareholders</i>		
Dividends paid	-	-
Net increase in shareholders' funds	<u>138,393</u>	54,584
Opening shareholders' funds	<u>274,356</u>	219,672
Closing shareholders' funds	<u>412,749</u>	<u>274,256</u>
12. Post balance sheet events and going concern		
There have been no significant event since the end of the year.		
13. Approval of financial statements		
The board of directors approved these financial statements for issue on .		